文献速递主动脉疾病外周动脉疾病

Lifetech髂动脉分叉支架系统腔内修复主髂动脉或髂总动脉瘤的前瞻性多中心临床研究

Endovascular Repair of Aortoiliac or Common Iliac Artery Aneurysm Using the Lifetech Iliac Bifurcation Stent Graft System: A Prospective Multicenter Clinical Study.
PubMed 文献 · Ann Vasc Surg · 2019-09-26

本研究纳入中国8中心2015年9月至2018年6月接受Lifetech髂动脉分叉支架系统(IBSG)植入的73例主髂动脉瘤或髂总动脉瘤患者,评估保留髂内动脉的安全性和有效性。主要终点为术后180天髂内动脉通畅率,59例可评估患者中为96.61%(57/59),总体技术成功率89.04%(65/73),无死亡、III型内漏、支架移位、扭结或断裂。

要点

  • IBSG系统用于主髂动脉或髂总动脉瘤腔内修复时保留髂内动脉,180天通畅率达96.61%。
  • 总体技术成功率为89.04%,围手术期及随访期无死亡、III型内漏或支架相关并发症。
  • 性功能障碍发生率1.69%,臀肌跛行发生率3.39%,并发症发生率低。

核心结论

  • IBSG植入系统在主髂动脉瘤或髂总动脉瘤腔内修复中保留髂内动脉安全有效,技术成功率和髂内动脉通畅率高、并发症率低。

研究设计与样本

  • 前瞻性多中心临床研究,纳入中国8个中心2015年9月至2018年6月接受IBSG植入的患者73例,平均年龄69.6岁,男性占91.8%。
  • 术后30天和180天进行临床和CT血管造影随访,主要终点为术后180天IBSG装置的髂内动脉通畅率。

主要发现

  • 主髂动脉瘤55例(75.34%),髂总动脉瘤18例(24.66%);单侧髂动脉瘤69例(94.52%),双侧4例(5.48%)。
  • 总体技术成功率为89.04%(65/73),术后180天髂内动脉通畅率为96.61%(57/59)。
  • 性功能障碍发生1例(1.69%),臀肌跛行2例(3.39%);术中和随访期间无死亡、III型内漏、支架移位、扭结或断裂。

临床怎么用

  • 对于需腔内修复主髂动脉瘤或髂总动脉瘤且需保留髂内动脉的患者,可考虑使用IBSG系统。
  • 术后应进行临床和CT血管造影随访以评估髂内动脉通畅性和支架相关并发症。

局限性

  • 随访时间仅至术后180天,长期耐久性需继续随访5年确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sacrifice of the internal iliac artery (IIA) may result in ischemic manifestations after aortoiliac aneurysm (AIA) or common iliac artery aneurysm (CIAA) endovascular repair. This study sought to evaluate the safety and efficacy of a new Iliac Bifurcation Stent Graft (IBSG; Lifetech Scientific, Shenzhen, China) system for revascularization of the IIA. METHODS: Patients who underwent implantation of the IBSG at 8 centers in China from September 2015 to June 2018 were enrolled. Clinical and computed tomography angiography follow-up assessments were conducted at 30 and 180 days postoperatively. The primary end point was the IIA patency rate of the IBSG device at 180 days postoperatively. Secondary end points comprised the postoperative technical success rate and clinical success rate at 30 and 180 days. Descriptive statistics and the Clopper-Pearson exact method were used to analyze the data. RESULTS: Seventy-three patients (mean age, 69.6 years; 91.8% men) were eligible for this trial, and 59 patients were eligible for primary effectiveness end-point analysis. AIA was present in 55 patients (75.34%) and CIAA in 18 patients (24.66%). The iliac artery aneurysms were unilateral in 69 patients (94.52%) and bilateral in 4 patients (5.48%). Overall technical success was 89.04% (65 of 73 patients). IIA patency at 180 days was 96.61% (57 of 59 patients). Sexual dysfunction occurred in 1 patient (1.69%), and 2 patients (3.39%) experienced buttock claudication. There was no mortality, type III endoleak, stent migration, kinking, or fracture during the procedure and follow-up. CONCLUSIONS: The IBSG implantation system is a safe and effective technique for IIA preservation during AIA or CIAA endovascular repair. The high technical success rate, IIA patency rate, and low complication rate are promising. Follow-up will be continued for 5 years to confirm the durability of the device.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zhang H, Zhang H, Dai X, et al. Endovascular Repair of Aortoiliac or Common Iliac Artery Aneurysm Using the Lifetech Iliac Bifurcation Stent Graft System: A Prospective Multicenter Clinical Study. Ann Vasc Surg. 2019. PMID: 31563658. doi:10.1016/j.avsg.2019.06.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。